NCT Number |
Title |
Conditions |
Interventions |
Sponsor
Collaborators |
Phases |
NCT03353597 |
Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects |
Aging |
Biological: Plasma Transfusion |
Chandra Duggirala
Fountain Labs, Inc. |
Phase 1
Phase 2 |
NCT03258554 |
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin |
Head and Neck Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 |
Biological: Cetuximab|Biological: Durvalumab|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Other: Questionnaire Administration |
National
Cancer Institute (NCI) |
Phase 2
Phase 3 |
NCT03371329 |
Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage |
Hemorrhagic Stroke|Intracerebral Hemorrhage |
Biological: MSC |
Mayo Clinic |
Phase 1 |
NCT03358719 |
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
Acute Myeloid Leukemia|Blasts 30 Percent or Less of Bone Marrow Nucleated Cells|Chronic Myelomonocytic Leukemia|High Risk Myelodysplastic Syndrome|Myelodysplastic Syndrome|Refractory Anemia |
Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Drug: Decitabine|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Poly ICLC |
Roswell Park Cancer Institute
National Cancer Institute (NCI) |
Phase 1 |
NCT03338972 |
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|TNFRSF17 Positive |
Biological: BCMA-specific CAR-expressing T Lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis |
Fred Hutchinson Cancer Research Center
Juno Therapeutics, Inc.
National Cancer Institute (NCI) |
Phase 1 |
NCT03304639 |
Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer |
Stage III Merkel Cell Carcinoma AJCC v7|Stage IIIA Merkel Cell Carcinoma AJCC v7|Stage IIIB Merkel Cell Carcinoma AJCC v7|Stage IV Merkel Cell Carcinoma AJCC v7 |
Biological: Pembrolizumab|Radiation: Stereotactic Body Radiation Therapy |
National Cancer Institute (NCI) |
Phase 2 |
NCT03274258 |
Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma |
Renal Medullary Carcinoma|Other Disorders of Kidney and Ureter |
Drug: Nivolumab|Drug: Ipilimumab |
M.D. Anderson Cancer Center
Bristol-Myers Squibb |
Phase 2 |
NCT03269552 |
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma |
Marginal Zone Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Waldenstrom Macroglobulinemia |
Drug: Carfilzomib|Other: Laboratory Biomarker Analysis|Biological: Rituximab |
University of Washington
National Cancer Institute (NCI) |
Phase 2 |
NCT03259425 |
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma |
Melanoma |
Drug: Nivolumab|Drug: HF10 |
University of Utah
Bristol-Myers Squibb
Takara Bio Inc. |
Phase 2 |
NCT03237377 |
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer |
Non-Small Cell Lung Cancer |
Drug: Durvalumab|Drug: Tremelimumab|Radiation: Thoracic Radiation |
Sidney Kimmel Comprehensive Cancer Center |
Phase 2 |
NCT03016377 |
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia |
Acute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative Disorders |
Biological: iC9-CAR19 cells|Drug: AP1903|Drug: Cyclophosphamide|Drug: Fludarabine |
UNC Lineberger Comprehensive Cancer Center |
Phase 1 |
NCT02833506 |
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer |
Other: Laboratory Biomarker Analysis|Biological: Recombinant NY-ESO-1 Protein|Drug: Sirolimus |
Roswell Park Cancer Institute
National Cancer Institute (NCI) |
Phase 1 |
NCT03257761 |
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer |
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type|Gallbladder Adenocarcinoma, Biliary Type|Metastatic Pancreatic Adenocarcinoma|Recurrent Cholangiocarcinoma|Recurrent Gallbladder Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Intrahepatic Cholangiocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Gallbladder Cancer AJCC V7|Stage III Hepatocellular Carcinoma AJCC v7|Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Gallbladder Cancer AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Gallbladder Carcinoma|Unresectable Pancreatic Carcinoma |
Biological: Durvalumab|Drug: Guadecitabine |
University of Southern California
National Cancer Institute (NCI) |
Phase 1 |
NCT03371381 |
An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung |
Adenocarcinoma of Lung |
Biological: JNJ-64041757|Drug: Nivolumab |
Janssen Research & Development, LLC |
Phase 1
Phase 2 |
NCT03273153 |
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma |
Advanced BRAFV600 Wild-type Melanoma |
Drug: Cobimetinib|Drug: Atezolizumab|Drug: Pembrolizumab |
Hoffmann-La Roche |
Phase 3 |
NCT03301896 |
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies |
Solid Tumors |
Drug: LHC165|Biological: PDR001 |
Novartis Pharmaceuticals
Novartis |
Phase 1 |